Digestion

 

Precise Role of Acid in Non-Erosive Reflux Disease

Wang C. · Hunt R.H.

Author affiliations

Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ont., Canada

Keywords: Gastroesophageal reflux diseaseNon-erosive reflux diseaseErosive esophagitisAcidResponse to acid suppression

Related Articles for ""
Digestion 2008;78:31–41
https://doi.org/10.1159/000151253

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 02, 2008
Issue release date: October 2008

Number of Print Pages: 11
Number of Figures: 2
Number of Tables: 1

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

The fundamental abnormality in gastroesophageal reflux disease is exposure of the esophageal epithelium to acidic gastric contents, resulting in histopathologic injury and/or symptoms. With increasing understanding of gastroesophageal reflux disease, non-erosive reflux disease (NERD) is found to account for >50% of cases involving gastroesophageal reflux. There is a good correlation between esophageal acid exposure (EAE) and endoscopic changes. Duration of EAE correlates with severity of erosive esophagitis (EE), and the number of prolonged acid reflux episodes and esophageal exposure to acid and pepsin is increased in more severe reflux. However, there is no convincing evidence to support a significant difference in the acid secretory capacity between patients with NERD or EE. Although acid reflux gives rise to similar symptoms in both NERD and EE patients, the underlying mechanism of acid injury may be different. Dilated intercellular spaces may be responsible for the enhanced perception of proximal acid reflux and dilated intercellular spaces are a feature of NERD patients, irrespective of EAE, and can be considered an objective, structural marker of reflux symptoms. Three different mechanisms have been proposed to explain the occurrence of heartburn in endoscopy-negative patients: esophageal visceral hypersensitivity, sustained esophageal contractions, and abnormal tissue resistance. Impaired esophageal mucosal resistance or increased sensitivity, even to small amounts of acid reflux, plays a key role in the pathophysiology of NERD. Moreover, hyperalgesia may be a predominant mechanism in eliciting symptoms in NERD patients. Increasingly seen are patients with a poor response to acid suppression treatment. Moreover, even double proton pump inhibitor dosing does not completely inhibit gastric acid secretion and relieve all symptoms. Thus, current definitions of acid reflux require review to increase the sensitivity to determine the frequency and implication of short periods of acidity in the esophagus. Analysis such as analysis of the area under the H+ activity time curve is one alternative approach for evaluating acid secretion. The precise role of acid in NERD needs further clarification.

© 2008 S. Karger AG, Basel



Related Articles:

References

  1. Fass R: Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131–137.
    External Resources
  2. Dent J, El-Serag HB, Wallander MA, et al: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710–717.
    External Resources
  3. Fock KM, Talley NJ, Fass R, et al: Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008;23:8–22.
    External Resources
  4. Dent J, Brun J, Fendrick AM, et al: An evidence-based appraisal of reflux disease management. The Genval workshop report. Gut 1999;44:S1–S16.
    External Resources
  5. Vakil N, van Zanten SV, Kahrilas P, et al: Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–1920.
    External Resources
  6. Tack J, Caenepeel P, Arts J, et al: Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005;54:1370–1376.
    External Resources
  7. Fass R: Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98(3 suppl):S2–S7.
    External Resources
  8. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656–664.
    External Resources
  9. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974–979.
    External Resources
  10. Barlow WJ, Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771–778.
    External Resources
  11. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R: Non-erosive reflux disease (NERD) – acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537–545.
    External Resources
  12. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP: Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457–464.
    External Resources
  13. Bate CM, Griffin SM, Keeling PW, Axon AT, Dronfield MW, Chapman RW, et al: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547–555.
    External Resources
  14. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119–124.
    External Resources
  15. Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PB: The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:891–905.
    External Resources
  16. Kahrilas PJ, Lee TJ: Pathophysiology of gastroesophageal reflux disease. Thorac Surg Clin 2005;15:323–333.
    External Resources
  17. Johnson LF, DeMeester TR: Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986;8(suppl 1):52–58.
    External Resources
  18. Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, et al: Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588–1598.
    External Resources
  19. Cadiot G, Bruhat A, Rigaud D, Coste T, Vuagnat A, Benyedder Y, et al: Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut 1997;40:167–174.
    External Resources
  20. Ho KY, Kang JY: Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western hemisphere. Am J Gastroenterol 1999;94:1186–1191.
    External Resources
  21. Tobey NA, Hosseini SS, Caymaz-Bor C, Wyatt HR, Orlando GS, Orlando RC: The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol 2001;96:3062–3070.
    External Resources
  22. Emerenziani S, Sifrim D, Habib FI, Ribolsi M, Guarino MP, Rizzi M, et al: Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut 2008;57:443–447.
    External Resources
  23. Nagahara A, Miwa H, Minoo T, Hojo M, Kawabe M, Osada T, et al: Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol 2006;40:891–895.
    External Resources
  24. Wu JC, Cheung CM, Wong VW, Sung JJ: Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:690–695.
    External Resources
  25. Kern MK, Birn RM, Jaradeh S, Jesmanowicz A, Cox RW, Hyde JS, et al: Identification and characterization of cerebral cortical response to esophageal mucosal acid exposure and distention. Gastroenterology 1998;115:1353–1362.
    External Resources
  26. Caviglia R, Ribolsi M, Maggiano N, et al: Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005;100:543–548.
    External Resources
  27. Chen CC, Zimmer A, Sun WH, et al: A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci USA 2002;99:8992–8997.
    External Resources
  28. Duan LJ, Wu LJ, Yu YQ, et al: Upregulation of acid-sensing ion channel ASIC1a in spinal dorsal horn neurons contributes to inflammatory pain hypersensitivity. J Neurosci 2007;27:11139–11148.
    External Resources
  29. Wemmie JA, Coryell MW, Askwith CC, et al: Overexpression of acid-sensing ion channel 1a in transgenic mice increases acquired fear-related behavior. Proc Natl Acad Sci USA 2004;101:3621–3626.
    External Resources
  30. Gao J, Duan B, Wang DG, et al: Coupling between NMDA receptor and acid-sensing ion channel contributes to ischemic neuronal death. Neuron 2005;48:635–646.
    External Resources
  31. Xiong ZG, Pignataro G, Li M, et al: Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol 2008;8:25–32.
    External Resources
  32. Hunt RH, Armstrong D, Yaghoobi M, et al: Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008;28:187–199.
  33. Smith JL, Opekun AR, Larkai E, Graham DY: Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989;96:683–689.
    External Resources
  34. Hunt RH: Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649–657.
    External Resources
  35. Nagahama K, Yamato M, Nishio H, Takeuchi K: Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis Sci 2006;51:303–309.
    External Resources
  36. Goldberg HI, Dodds WJ, Gee S, Montgomery C, Zboralske FF: Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 1969;56:223–230.
    External Resources
  37. Gotley DC, Morgan AP, Ball D, Owen RW, Cooper MJ: Composition of gastro-oesophageal refluxate. Gut 1991;32:1093–1099.
    External Resources
  38. Vaezi MF, Richter JE: Synergism of acid and duodenogastroesophageal reflux in complicated Barrett’s esophagus. Surgery 1995;117: 699–704.
    External Resources
  39. Lillemoe KD, Johnson LF, Harmon JW: Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus. Gastro- enterology 1983;85:621–628.
  40. Hunt RH: The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(suppl 1):3–7.
    External Resources
  41. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798–1810.
    External Resources
  42. Talley NJ: Review article: gastro-oesophageal reflux disease – how wide is its span? Aliment Pharmacol Ther 2004;20(suppl 5): 27–37; discussion 38–39.
    External Resources
  43. Giamberardino MA: Recent and forgotten aspects of visceral pain. Eur J Pain 1999;3:77–92.
    External Resources
  44. Drewes AM, Reddy H, Pedersen J, Funch-Jensen P, Gregersen H, Arendt-Nielsen L: Multimodal pain stimulations in patients with grade B oesophagitis. Gut 2006;55:926–932.
    External Resources
  45. Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995;37:7–12.
    External Resources
  46. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr: Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999;94:628–631.
    External Resources
  47. Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J, et al: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363–1373.
    External Resources
  48. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC: Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995;40:1607–1613.
    External Resources
  49. Burdette BH, Gale EN: Pain as a learned response: a review of behavioral factors in chronic pain. J Am Dent Assoc 1988;116:881–885.
    External Resources
  50. Ismail-Beigi F, Horton PF, Pope CE: Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970;58:163–174.
    External Resources
  51. Ismail-Beigi F, Pope CE: Distribution of the histological changes of gastroesophageal reflux disease in the distal esophagus of man. Gastroenterology 1974;66:1109–1113.
    External Resources
  52. Nakamura T, Shirakawa K, Masuyama H, et al: Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 2005;21 (suppl 2):19–26.
    External Resources
  53. Hongo M: Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 2006;41:95–99.
    External Resources
  54. Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, et al: Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005;100:2299–2306.
    External Resources
  55. Kiesslich R, Kanzler S, Vieth M, Moehler M, Neidig J, Thanka Nadar BJ, et al: Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis 2004;22:221–227.
    External Resources
  56. Tobey NA, Carson JL, Alkiek RA, et al: Dilated intercellular spaces: a morphological feature of acid reflux – damaged human esophageal epithelium. Gastroenterology 1996;111:1200–1205.
    External Resources
  57. Calabrese C, Fabbri A, Bortolotti M, et al: Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003;18:525–532.
    External Resources
  58. Caviglia R, Ribolsi M, Gentile M, et al: Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;25:629–636.
    External Resources
  59. Vieth M, Fiocca R, Haringsma J, et al: Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesions. Dig Dis 2004;22:208–212.
    External Resources
  60. Calabrese C, Bortolotti M, Fabbri A, Areni A, Cenacchi G, Scialpi C, et al: Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005;100:537–542.
    External Resources
  61. van Malenstein H, Farré R, Sifrim D: Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2007, Epub ahead of print.
  62. The Rome II International Working Teams: Functional heartburn; in Drossman DA, Corazziari E, Talley NJ, et al (eds): Rome II: The Functional Gastrointestinal Disorders, ed 2. Lawrence, Alle Press, 2000, pp 275–278.
  63. Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, et al: Functional esophageal disorders. Gastroenterology 2006;130:1459–1465.
    External Resources
  64. Fass R, Fennerty MB, Vakil N: Nonerosive reflux disease – current concepts and dilemmas. Am J Gastroenterol 2001;96:303–314.
    External Resources
  65. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997–2000.
    External Resources
  66. Johnsson F, Weywadt L, Solhaug JH, et al: One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15–20.
    External Resources
  67. Fass R, Ofman JJ, Gralnek IM, et al: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161–2168.
    External Resources
  68. Shapiro M, Green C, Bautista JM, et al: Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006;101:1084–1091.
    External Resources
  69. Johnson LF, DeMeester TR: Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974;62:325–332.
    External Resources
  70. Vitale GC, Cheadle WG, Sadek S, Michel ME, Cuschieri A: Computerized 24-hour ambulatory esophageal pH monitoring and esophagogastroduodenoscopy in the reflux patient. A comparative study. Ann Surg 1984;200:724–728.
    External Resources
  71. Kahrilas PJ, Quigley EM: Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996;110:1982–1996.
    External Resources
  72. Hirano I: Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease – Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Aliment Pharmacol Ther 2006;23(suppl 1):12– 24.
    External Resources
  73. Somani SK, Ghoshal UC, Saraswat VA, Aggarwal R, Misra A, Krishnani N, et al: Correlation of esophageal pH and motor abnormalities with endoscopic severity of reflux esophagitis. Dis Esophagus 2004;17:58–62.
    External Resources
  74. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ: Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci 2002;47:2565–2573.
    External Resources
  75. Gardner JD, Rodriguez-Stanley S, Robinson M: Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol 2001;96:1363–1370.
    External Resources
  76. Gardner JD, Sloan S, Miner PB, Robinson M: Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro- oesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003;17:955–964.
    External Resources
  77. Gledhill T, Buck M, Hunt RH: Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders. Gut 1984;25:1211– 1216.
    External Resources
  78. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763–767.
    External Resources
  79. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335–1339.
    External Resources
  80. Fackler WK, Ours TM, Vaezi MF, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625–632.
    External Resources
  81. Gardner JD, Sloan S, Robinson M, Miner PB: GERD subjects with increased nocturnal esophageal acidity have increased nocturnal gastric acidity. Am J Gastroenterol 2005;100(suppl 9):S24.
  82. Katz PO, Castell DO, Chen Y, et al: Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004;20:399–406.
    External Resources
  83. Miehlke S, Madisch A, Kirsch C, et al: Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment Pharmacol Ther 2005;21:963–967.
    External Resources
  84. Hunt RH, Armstrong D, Yaghoobi M, et al: Inhibition of acid secretion by a novel proton pump inhibitor (PPI). Gastroenterology 2007;132(suppl 2):A486.
  85. Richter JE: How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007;4:658–664.
    External Resources
  86. Fass R, Shapiro M, Dekel R, et al: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005;22:79–94.
    External Resources
  87. Bredenoord AJ, Smout AJ: Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008;20:217–223.
    External Resources
  88. Hunt RH, Yuan Y, Mohammad Y: GERD: new strategies and new failures. J Clin Gastroenterol 2007;41(suppl 2):S72–S80.
    External Resources
  89. Richter JE, Campbell DR, Kahrilas PJ, et al: Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803–1809.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 02, 2008
Issue release date: October 2008

Number of Print Pages: 11
Number of Figures: 2
Number of Tables: 1

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2008, Vol.78, Suppl. 1

October 2008

Article

Recommend This
TOP